105 related articles for article (PubMed ID: 26883404)
1. Implementation of a Lung Cancer Nurse Navigator Enhances Patient Care and Delivery of Systemic Therapy at the British Columbia Cancer Agency, Vancouver.
Zibrik K; Laskin J; Ho C
J Oncol Pract; 2016 Mar; 12(3):e344-9. PubMed ID: 26883404
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
[TBL] [Abstract][Full Text] [Related]
3. Wait times in diagnostic evaluation and treatment for patients with stage III non-small cell lung cancer in British Columbia.
Wai ES; Mackinnon M; Hooker R; Moccia P; Perry KR; Truong PT
Am J Clin Oncol; 2012 Aug; 35(4):373-7. PubMed ID: 21422900
[TBL] [Abstract][Full Text] [Related]
4. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
5. Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study.
Hilzenrat RA; Yip S; Melosky B; Ho C; Laskin J; Sun S; Choi JJ; McGuire AL
Curr Oncol; 2022 Dec; 30(1):145-156. PubMed ID: 36661661
[TBL] [Abstract][Full Text] [Related]
6. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
[TBL] [Abstract][Full Text] [Related]
7. Waiting times in early-stage non-small cell lung cancer (NSCLC).
Saint-Jacques N; Rayson D; Al-Fayea T; Virik K; Morzycki W; Younis T
J Thorac Oncol; 2008 Aug; 3(8):865-70. PubMed ID: 18670304
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
[TBL] [Abstract][Full Text] [Related]
10. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
11. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
12. Education and referral criteria: impact on oncology referrals to palliative care.
Reville B; Reifsnyder J; McGuire DB; Kaiser K; Santana AJ
J Palliat Med; 2013 Jul; 16(7):786-9. PubMed ID: 23510168
[TBL] [Abstract][Full Text] [Related]
13. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified.
Ho C; Tong KM; Ramsden K; Ionescu DN; Laskin J
Curr Oncol; 2015 Jun; 22(3):e164-70. PubMed ID: 26089727
[TBL] [Abstract][Full Text] [Related]
14. Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care.
Tanvetyanon T; Lee JH; Fulp WJ; Schreiber F; Brown RH; Levine RM; Cartwright TH; Abesada-Terk G; Kim GP; Alemany C; Faig D; Sharp PV; Markham MJ; Malafa M; Jacobsen PB
J Oncol Pract; 2014 Jul; 10(4):e247-54. PubMed ID: 24737876
[TBL] [Abstract][Full Text] [Related]
15. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Ellis PM; Verma S; Sehdev S; Younus J; Leighl NB
J Thorac Oncol; 2013 Sep; 8(9):1136-41. PubMed ID: 23887170
[TBL] [Abstract][Full Text] [Related]
16. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
18. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
[TBL] [Abstract][Full Text] [Related]
19. Integration of a nurse navigator into the triage process for patients with non-small-cell lung cancer: creating systematic improvements in patient care.
Zibrik K; Laskin J; Ho C
Curr Oncol; 2016 Jun; 23(3):e280-3. PubMed ID: 27330366
[TBL] [Abstract][Full Text] [Related]
20. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Mariano C; Bosdet I; Karsan A; Ionescu D; Murray N; Laskin JJ; Zhai Y; Melosky B; Sun S; Ho C
Lung Cancer; 2014 Jan; 83(1):73-7. PubMed ID: 24192511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
